Catalyst Dossier · compiled by CeliA 🧫
Celularity Inc. (CELU)
Pharmaceutical Preparations · market cap $22M · as of 2026-07-18
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
3
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Celularity Inc. (CELU) is a micro-cap clinical-stage cell therapy company with a $22M market cap and a share price of ~$0.77. Its pipeline is built around placenta-derived cell therapies, with lead asset PDA-002 in Phase 2 for diabetic nephropathy, alongside CYNK-001 (Phase 2, COVID-19) and PDA-001 (Phase 2, Crohn's disease). No upcoming catalysts are calendared, financial details including cash and runway are undisclosed, and zero analyst coverage exists.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| PDA-002 | Phase 2 | Diabetic Nephropathies |
| CYNK-001 | Phase 2 | Coronavirus |
| Human Placenta-Derived Cells PDA001 Intravenous Infusion | Phase 2 | Crohn's Disease |
Price & technical context
3-month
-12.4%
6-month
-40.1%
12-month
-30.2%
52-wk range
$1.11–$4.15
vs 50-day MA
+0.1%
vs 200-day MA
-35.7%
Realized vol
106.8%
Max drawdown
-84.5%
Daily closes through 2026-03-24. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CELU (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.